|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2005-10-13
|
|
pubmed:abstractText |
The purpose of this study was to determine the feasible adjuvant therapy administration schedule of S-1 for locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN). Patients receiving definitive treatments were randomly assigned to either arm A (51 cases) receiving oral S-1 of 2-week administration followed by 1-week rest for 6 months, or arm B receiving S-1 of 4-week administration followed by 2-week rest for 6 months. Planned treatment was given in 40% of patients in arm A and 29% in arm B. The cumulative rates of the relative total administration dose of S-1 at 100% were 54.9% (95% CI: 40.1-69.7%) in arm A and 34.3% (95% CI: 21.1-47.4%) in arm B, respectively (P=0.054). Adverse events were recorded in 41 patients (82.0%) in arm A and 48 patients (94.1%) in arm B (P=0.060). The incidences of diarrhoea (10 vs 28%; P<0.05) and skin toxicities (18 vs 37%; P<0.05) were significantly higher in arm B. One-year disease-free survival was similar in both arms: arm A 81.2% (95% CI: 70.0-92.4%); arm B 77.0% (95% CI: 65.0-89.0%). The schedule of 2-week administration followed by 1-week rest seems to be more feasible for oral 6-month administration of S-1 in adjuvant chemotherapy of locoregionally advanced SCCHN.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-10200775,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-10765119,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-10768432,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-10901361,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-11681245,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-12176777,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-12518365,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-14645636,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-15041712,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-15102997,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-15117998,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-15128893,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-15224197,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-15277256,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-15505626,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-15747168,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-15800310,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-1618662,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-2185340,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-2433406,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-8031158,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-8630927,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-8653704,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-8862723,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16189518-9893658
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
17
|
|
pubmed:volume |
93
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
884-9
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:16189518-Administration, Oral,
pubmed-meshheading:16189518-Adult,
pubmed-meshheading:16189518-Aged,
pubmed-meshheading:16189518-Antimetabolites, Antineoplastic,
pubmed-meshheading:16189518-Carcinoma, Squamous Cell,
pubmed-meshheading:16189518-Chemotherapy, Adjuvant,
pubmed-meshheading:16189518-Disease-Free Survival,
pubmed-meshheading:16189518-Drug Administration Schedule,
pubmed-meshheading:16189518-Drug Combinations,
pubmed-meshheading:16189518-Female,
pubmed-meshheading:16189518-Head and Neck Neoplasms,
pubmed-meshheading:16189518-Humans,
pubmed-meshheading:16189518-Male,
pubmed-meshheading:16189518-Middle Aged,
pubmed-meshheading:16189518-Oxonic Acid,
pubmed-meshheading:16189518-Pyridines,
pubmed-meshheading:16189518-Tegafur,
pubmed-meshheading:16189518-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer.
|
|
pubmed:affiliation |
Department of Biology and Function in the Head and Neck, Yokohama City University Graduate School of Medicine, Kanazawa-ku, Yokohama, Japan. mtsukuda@med.yokohama-cu.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
